ReviewInfection2026
Recent advances in clinical and laboratory diagnosis of hydatid cyst: from imaging to recombinant and nanobiosensor-based approaches.
Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic echinococcosis is a significant parasitic disease that predominantly affects the liver and lungs in humans. Its diagnosis relies mainly on imaging techniques such as ultrasound and computed tomography, supported byserological tests, including enzyme-linked immunosorbent assay and immunoblotting, which are commonly used inhuman serodiagnosis. Conventional serological assays frequently show variable sensitivity, particularly in pulmonary, inactive, or calcified cysts, and may yield false-negative or cross-reactive results.
methodsRecent advances in recombinant antigen-based assays and nanobiosensors technologies have further improved diagnostic sensitivity and specificity. Current studies on recombinant antigens such as 2B2t, P29, and multiepitope constructs have markedly improved diagnostic performance compared with crude hydatid fluid preparations.
resultsThe combination of these methods enhances diagnostic accuracy.
conclusionThis review focuses explicitly on diagnostic approaches in humans, with emphasis on immunological, serological, and emerging biotechnological tools. Given the considerable variability in the performance of individual techniques, a combined, multidisciplinary diagnostic approach is essential for early and accurate detection, ultimately improving clinical management and patient outcomes. Integrating high-performance recombinant antigens with nanotechnology-enhanced detection systems may shape the next generation of CE diagnostics, particularly in endemic and low-resource regions.
Indexed as
Identifiers
41849030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.